Health Care/Hospital
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a re...
2026-10-24 09:26
4908
Dimora Medical Supports Empower HS 2026, Advancing Everyday Wound Care for the HS Community
- Silicone foam dressings featuring MegaSorb™ technology were included in attendee gift bags to support at-home management of exuding wounds NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Dimora Medical, a pioneer in professional wound care, supported the HS Connect Empower Conference 2026. Taking ...
2026-10-24 01:50
2819
Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy - Nucleic Acids
* Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting skeletal muscle, heart, and adipose tissue—and localized routes across ocular, joint, and bladder compartments * Unlocks high-value therapeutic tissues for neuromuscular, car...
2026-10-23 21:35
4380
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
* Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer * Arcotatug Tavatecan Demonstrated a Favorabl...
2026-10-23 20:00
2311
Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.
* Secures its 13th FDA 510(k) clearance, expanding its U.S. portfolio from lung nodule detection and coronary artery calcium (CAC) analysis to quantitative aortic assessment * Enables automated aortic segmentation and diameter measurements across anatomical regions, broadening the quantitativ...
2026-10-23 20:00
2779
HoneyNaps Selected for 2026 Eurostars International R&D Project
* Korean-Swedish consortium brings together Yonsei University, Dankook University, Uppsala University and Xantage AB * Project to develop a non-invasive platform for neurological monitoring * Skin-mounted sensors aim to track changes in intracranial pressure continuously, alongside sleep ...
2026-10-23 18:00
1647
NUH OPHTHALMOLOGY AT 40: FOUR DECADES OF TRANSFORMING EYE CARE
The Department marks its anniversary by spotlighting innovations in multidisciplinary and minimally invasive care, alongside a flagship international congress that fosters global collaboration in ophthalmology SINGAPORE, Oct. 23, 2026 /PRNewswire/ -- As the Department of Ophthalmology at the Nat...
2026-10-23 15:22
1261
2026 CSCCP-ASCCP Colposcopy Training Course--Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions
* Advancing Precision Diagnosis and Treatment * Photodynamic Therapy Introduced for the First Time into Colposcopy Faculty Training in China WUHAN, China, Oct. 23, 2026 /PRNewswire/ -- The 2026 CSCCP-ASCCP Colposcopy Training Course, held in Wuhan from October 21 to 23, concluded successfully...
2026-10-23 14:03
1746
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026
SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in BIO-...
2026-10-23 10:07
1734
Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the disc...
2026-10-23 08:02
2336
ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026
SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011,will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These p...
2026-10-23 08:00
1868
Tairex Launches Multi-Agent AI System to Transform Clinical Collaboration and Decision Support
BEIJING, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, unveiled the Multidisciplinary Human-Agent Collaboration (MHAC) Ecosystem for Agent Hospital, designed to enable spec...
2026-10-22 23:00
1772
Vespexx Recognized as Finalist for the Digital Health Hub Foundation Digital Health & AI Awards 2026 at HLTH
SEOUL, South Korea, Oct. 22, 2026 /PRNewswire/ -- Vespexx Inc., an AI-driven femtech company,today announced it has been named a Finalist for the Digital Health Hub Foundation's Digital Health & AI Awards 2026, held at HLTH. Competing in the Rising Star track under the Women's & Family Health cat...
2026-10-22 21:00
2999
Ping An Unveils China's First Brain Health Service Management Program, Focused on Alzheimer's Prevention and Care
HONG KONG and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Ping An Insurance (Group) Company of China ("Ping An") unveiled China's first Brain Health Service Management Program at a seminar in Beijing on proactive Alzheimer's management and brain health services. At the event, Ping An ...
2026-10-22 18:12
3146
HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
* Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity * Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational...
2026-10-22 18:00
1867
Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission
SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA...
2026-10-22 13:30
1683
NUH WINS GOLD AT IHF AWARDS 2026 FOR GREEN OPERATING THEATRE PROGRAMME
NUH won Gold and received an Honourable Mention for its sustainability efforts at the International Hospital Federation Awards 2026, alongside presentations of its green surgical initiatives, digital health and organisational improvement initiatives at the World Hospital Congress. SINGAPORE, Oc...
2026-10-22 09:27
4051
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
* Becomes the 7th International Registrational Clinical Trial for Ivonescimab * Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its ...
2026-10-21 20:42
2159
China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"),today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termi...
2026-10-21 20:00
2990
Samsung Biologics Reports Third Quarter 2026 Financial Results
* Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion * Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance * Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion...
2026-10-21 15:00
2933
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 275 media titles]
2026-10-23 21:52
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
24286
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
21040
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
19072
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
17552